{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:29:41Z","timestamp":1792416581663,"version":"4.4.0"},"reference-count":59,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:p>OBJECTIVES. To assess whether targeted short-term fluconazole prophylaxis reduces late-onset (&amp;gt;3 days of age) invasive fungal infection (IFI) among very low birth weight infants and extremely low birth weight (ELBW) infants and to assess mortality rates, toxicity, and costs associated with this intervention.<\/jats:p>\n               <jats:p>METHODS. An observational study of 2 subsequent epochs of inborn infants with birth weight of &amp;lt;1500 g or gestational age of &amp;lt;32 weeks, 1 before (control) and 1 after (fluconazole) initiation of routine targeted fluconazole prophylaxis in March 2003, was performed. Targeted fluconazole (3 mg\/kg) prophylaxis was administered to infants for whom a decision was made to administer broad-spectrum antibiotics for &amp;gt;3 days.<\/jats:p>\n               <jats:p>RESULTS. IFI was observed for 13 (6.3%) of 206 infants in the control epoch and 2 (1.1%) of 178 in the fluconazole epoch, with a common odds ratio of 0.166. Logistic regression analysis taking into account all published factors (except for fungal colonization) showed that the fluconazole epoch was associated significantly with lower IFI rates. We observed no change in late (&amp;gt;3 days) mortality rates (11 of 206 infants in the control epoch vs 8 of 178 infants in the prophylaxis epoch). The mortality rate for ELBW infants with IFI was low (15%) in our study. Fluconazole was administered to 81% of ELBW infants, who received a median of 8 doses, and 41% of larger infants, who received a median of 5 doses. The intervention was cost-effective, and the effective number needed to treat to prevent 1 IFI was 10.<\/jats:p>\n               <jats:p>CONCLUSIONS. This study suggests that targeted short-course fluconazole prophylaxis in very low birth weight and ELBW infants may be efficacious and cost effective.<\/jats:p>","DOI":"10.1542\/peds.2005-1969","type":"journal-article","created":{"date-parts":[[2006,4,3]],"date-time":"2006-04-03T21:23:11Z","timestamp":1144099391000},"page":"1243-1252","source":"Crossref","is-referenced-by-count":97,"title":["Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants"],"prefix":"10.1542","volume":"117","author":[{"given":"Smart","family":"Uko","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia M.","family":"Soghier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Marsh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald T.","family":"Reinersman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Herring","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"},{"name":"Department of Infectious Diseases, Albert Einstein College of Medicine, Children\u2019s Hospital at Montefiore, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral A.","family":"Dave","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas","family":"Nafday","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc P.","family":"Brion","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"2021120902151140300_R1","doi-asserted-by":"crossref","unstructured":"Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J.\u20082000;19:319\u2013324","DOI":"10.1097\/00006454-200004000-00011"},{"key":"2021120902151140300_R2","doi-asserted-by":"crossref","unstructured":"Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics.\u20082002;110:285\u2013291","DOI":"10.1542\/peds.110.2.285"},{"key":"2021120902151140300_R3","unstructured":"Karlowicz MG, Rowen JL, Barnes-Eley ML, et al. The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study. Pediatr Res.\u20082002;51:301A"},{"key":"2021120902151140300_R4","doi-asserted-by":"crossref","unstructured":"Kaufman D. Fungal infection in the very low birthweight infant. Curr Opin Infect Dis.\u20082004;17:253\u2013259","DOI":"10.1097\/00001432-200406000-00014"},{"key":"2021120902151140300_R5","doi-asserted-by":"crossref","unstructured":"Benjamin DK, DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark RH. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics.\u20082003;112:543\u2013547","DOI":"10.1542\/peds.112.3.543"},{"key":"2021120902151140300_R6","doi-asserted-by":"crossref","unstructured":"Feja KN, Wu F, Roberts K, et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr.\u20082005;147:156\u2013161","DOI":"10.1016\/j.jpeds.2005.02.021"},{"key":"2021120902151140300_R7","doi-asserted-by":"crossref","unstructured":"Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr.\u20081996;129:63\u201371","DOI":"10.1016\/S0022-3476(96)70191-9"},{"key":"2021120902151140300_R8","doi-asserted-by":"crossref","unstructured":"Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics.\u20082002;109:34\u201339","DOI":"10.1542\/peds.109.1.34"},{"key":"2021120902151140300_R9","doi-asserted-by":"crossref","unstructured":"R\u00f8nnestad A, Abrahamsen TG, Medb\u00f8 S, et al. Late-onset septicemia in a Norwegian national cohort of extremely premature infants receiving very early full human milk feeding. Pediatrics.\u20082005;115(3). Available at: www.pediatrics.org\/cgi\/content\/full\/115\/3\/e269","DOI":"10.1542\/peds.2004-1833"},{"key":"2021120902151140300_R10","doi-asserted-by":"crossref","unstructured":"International Neonatal Network. The CRIB (Clinical Risk Index for Babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. Lancet.\u20081993;342:193\u2013198","DOI":"10.1016\/0140-6736(93)92296-6"},{"key":"2021120902151140300_R11","unstructured":"Cotton CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. Center differences in candidemia among extremely low birthweight (ELBW) infants: influence of antibiotic practices. PAS.\u20082005;57:644"},{"key":"2021120902151140300_R12","doi-asserted-by":"crossref","unstructured":"Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev.\u20082004;(3):CD004291","DOI":"10.1002\/14651858.CD004291.pub2"},{"key":"2021120902151140300_R13","doi-asserted-by":"crossref","unstructured":"G\u00f8tzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev.\u20082002;(2):CD000026","DOI":"10.1002\/14651858.CD000026"},{"key":"2021120902151140300_R14","doi-asserted-by":"crossref","unstructured":"McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev.\u20082004;(1):CD003850","DOI":"10.1002\/14651858.CD003850.pub2"},{"key":"2021120902151140300_R15","doi-asserted-by":"crossref","unstructured":"Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect.\u20082004;10(suppl 1):86\u201395","DOI":"10.1111\/j.1470-9465.2004.00847.x"},{"key":"2021120902151140300_R16","doi-asserted-by":"crossref","unstructured":"Vanden Bossche H, Marichal P, Gorrens J, et al. Biochemical approaches to selective antifungal activity: focus on azole antifungals. Mycoses.\u20081989;32(suppl 1):35\u201352","DOI":"10.1111\/j.1439-0507.1989.tb02293.x"},{"key":"2021120902151140300_R17","doi-asserted-by":"crossref","unstructured":"Trzaskos JM, Henry MJ. Comparative effects of the azole-based fungicide flusilazole on yeast and mammalian lanosterol 14\u03b1-methyl demethylase. Antimicrob Agents Chemother.\u20081989;33:1228\u20131231","DOI":"10.1128\/AAC.33.8.1228"},{"key":"2021120902151140300_R18","doi-asserted-by":"crossref","unstructured":"Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis.\u20081996;173:219\u2013225","DOI":"10.1093\/infdis\/173.1.219"},{"key":"2021120902151140300_R19","unstructured":"Burwell LA, Kaufman D, Stoll BJ, Tuboku-Metzger J, Fridkin SK. Prevention of neonatal candidemia in the United States: description of current antifungal prophylaxis practices of neonatologists, 2004. PAS.\u20082005;57:646"},{"key":"2021120902151140300_R20","unstructured":"Young TE, Mangum B. Neofax. 16th ed. Raleigh, NC: Acorn Publishing; 2003"},{"key":"2021120902151140300_R21","doi-asserted-by":"crossref","unstructured":"Benjamin DK, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics.\u20082003;112:634\u2013640","DOI":"10.1542\/peds.112.3.634"},{"key":"2021120902151140300_R22","doi-asserted-by":"crossref","unstructured":"Austin NC, Darlow B. Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev.\u20082004;(1):CD003478","DOI":"10.1002\/14651858.CD003478.pub2"},{"key":"2021120902151140300_R23","doi-asserted-by":"crossref","unstructured":"Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics.\u20082001;107:293\u2013298","DOI":"10.1542\/peds.107.2.293"},{"key":"2021120902151140300_R24","doi-asserted-by":"crossref","unstructured":"Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med.\u20082001;345:1660\u20131666","DOI":"10.1056\/NEJMoa010494"},{"key":"2021120902151140300_R25","unstructured":"Cabrera C, Frank M, Carter D, Bhatia J. Fluconazole prophylaxis against systemic candidiasis after colonization: a randomized, double-blinded study. J Perinatol.\u20082002;22:604"},{"key":"2021120902151140300_R26","doi-asserted-by":"crossref","unstructured":"Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics.\u20082001;107:404\u2013406","DOI":"10.1542\/peds.107.2.404"},{"key":"2021120902151140300_R27","doi-asserted-by":"crossref","unstructured":"Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of &lt;1000 grams birth weight. J Pediatr.\u20082005;147:172\u2013179","DOI":"10.1016\/j.jpeds.2005.03.036"},{"key":"2021120902151140300_R28","doi-asserted-by":"crossref","unstructured":"Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr.\u20082005;147:166\u2013171","DOI":"10.1016\/j.jpeds.2005.04.016"},{"key":"2021120902151140300_R29","doi-asserted-by":"crossref","unstructured":"Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr.\u20082005;147:162\u2013165","DOI":"10.1016\/j.jpeds.2005.02.020"},{"key":"2021120902151140300_R30","doi-asserted-by":"crossref","unstructured":"Roilides E, Farmaki E, Evdoridou J, et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis.\u20082004;23:745\u2013750","DOI":"10.1007\/s10096-004-1210-9"},{"key":"2021120902151140300_R31","unstructured":"Chong E, Kazzi NJ. End organ damage in Candida albicans and Candida parapsilosis infections among very low birth weight infants. PAS.\u20082005;57:648"},{"key":"2021120902151140300_R32","doi-asserted-by":"crossref","unstructured":"Arendrup M, Horn T, Frimodt-Moller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection.\u20082002;30:286\u2013291","DOI":"10.1007\/s15010-002-2131-0"},{"key":"2021120902151140300_R33","doi-asserted-by":"crossref","unstructured":"Huan YC, Li CC, Lin TY, et al. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J.\u20081998;17:819","DOI":"10.1097\/00006454-199809000-00014"},{"key":"2021120902151140300_R34","doi-asserted-by":"crossref","unstructured":"Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother.\u20081999;43:1955\u20131960","DOI":"10.1128\/AAC.43.8.1955"},{"key":"2021120902151140300_R35","doi-asserted-by":"crossref","unstructured":"Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med.\u20082001;344:984\u2013996","DOI":"10.1056\/NEJM200103293441307"},{"key":"2021120902151140300_R36","doi-asserted-by":"crossref","unstructured":"Katz HI. Drugs interactions of the newer oral antifungal agents. Br J Dermatol.\u20081999;141(suppl 56):26\u201332","DOI":"10.1046\/j.1365-2133.1999.00011.x"},{"key":"2021120902151140300_R37","doi-asserted-by":"crossref","unstructured":"Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother.\u20082002;50:231\u2013240","DOI":"10.1093\/jac\/dkf101"},{"key":"2021120902151140300_R38","doi-asserted-by":"crossref","unstructured":"Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis.\u20082001;33:1069\u20131075","DOI":"10.1086\/322641"},{"key":"2021120902151140300_R39","doi-asserted-by":"crossref","unstructured":"Chryssanthou E, Cherif H, Petrini B, Kalin M, Bjorkholm M. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis.\u20082004;36:855\u2013859","DOI":"10.1080\/00365540410021108"},{"key":"2021120902151140300_R40","doi-asserted-by":"crossref","unstructured":"Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol.\u20082004;42:1519\u20131527","DOI":"10.1128\/JCM.42.4.1519-1527.2004"},{"key":"2021120902151140300_R41","doi-asserted-by":"crossref","unstructured":"Sarvikivi E, Lyytikainen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol.\u20082005;43:2729\u20132735","DOI":"10.1128\/JCM.43.6.2729-2735.2005"},{"key":"2021120902151140300_R42","doi-asserted-by":"crossref","unstructured":"Marr KA, Lyons CN, Rustad T, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother.\u20081998;42:2584\u20132589","DOI":"10.1128\/AAC.42.10.2584"},{"key":"2021120902151140300_R43","doi-asserted-by":"crossref","unstructured":"Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschha\u0308user J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother.\u20081998;42:3065\u20133072","DOI":"10.1128\/AAC.42.12.3065"},{"key":"2021120902151140300_R44","doi-asserted-by":"crossref","unstructured":"Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother.\u20082005;49:668\u2013679","DOI":"10.1128\/AAC.49.2.668-679.2005"},{"key":"2021120902151140300_R45","doi-asserted-by":"crossref","unstructured":"Chen CG, Yang YL, Shih HI, Su SL, Lo HJ. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother.\u20082004,48:4505\u20134512","DOI":"10.1128\/AAC.48.12.4505-4512.2004"},{"key":"2021120902151140300_R46","doi-asserted-by":"crossref","unstructured":"Kamai Y, Maebashi K, Kudoh M, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol.\u20082004;48:937\u2013943","DOI":"10.1111\/j.1348-0421.2004.tb03623.x"},{"key":"2021120902151140300_R47","doi-asserted-by":"crossref","unstructured":"Liu TT, Lee RE, Barker KS, et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother.\u20082005;49:2226\u20132236","DOI":"10.1128\/AAC.49.6.2226-2236.2005"},{"key":"2021120902151140300_R48","doi-asserted-by":"crossref","unstructured":"Roemer T, Jiang B, Davison J, et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol.\u20082003;50:167\u2013181","DOI":"10.1046\/j.1365-2958.2003.03697.x"},{"key":"2021120902151140300_R49","doi-asserted-by":"crossref","unstructured":"Hooshdaran MZ, Barker KS, Hilliard GM, Kusch H, Morschhauser J, Rogers PD. Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother.\u20082004;48:2733\u20132735","DOI":"10.1128\/AAC.48.7.2733-2735.2004"},{"key":"2021120902151140300_R50","unstructured":"Hooshdaran MZ, Hilliard GM, Rogers PD. Application of proteomic analysis to the study of azole antifungal resistance in Candida albicans. Methods Mol Med.\u20082005;118:57\u201370"},{"key":"2021120902151140300_R51","doi-asserted-by":"crossref","unstructured":"Bruneau JM, Maillet I, Tagat E, et al. Drug induced proteome changes in Candida albicans: comparison of the effect of \u03b2(1,3)glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics.\u20082003;3:325\u2013336","DOI":"10.1002\/pmic.200390046"},{"key":"2021120902151140300_R52","doi-asserted-by":"crossref","unstructured":"White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother.\u20081997;41:1482\u20131487","DOI":"10.1128\/AAC.41.7.1482"},{"key":"2021120902151140300_R53","doi-asserted-by":"crossref","unstructured":"Redding SW, Kirkpatrick WR, Saville S, et al. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol.\u20082003;41:619\u2013622","DOI":"10.1128\/JCM.41.2.619-622.2003"},{"key":"2021120902151140300_R54","doi-asserted-by":"crossref","unstructured":"Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol.\u20082005;43:4434\u20134440","DOI":"10.1128\/JCM.43.9.4434-4440.2005"},{"key":"2021120902151140300_R55","doi-asserted-by":"crossref","unstructured":"Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr.\u20082005;147:135\u2013141","DOI":"10.1016\/j.jpeds.2005.04.033"},{"key":"2021120902151140300_R56","doi-asserted-by":"crossref","unstructured":"Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther.\u20081993;54:269\u2013277","DOI":"10.1038\/clpt.1993.147"},{"key":"2021120902151140300_R57","unstructured":"Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos.\u20081991;19:764\u2013767"},{"key":"2021120902151140300_R58","doi-asserted-by":"crossref","unstructured":"Frattarelli DA, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs.\u20082004;64:949\u2013968","DOI":"10.2165\/00003495-200464090-00003"},{"key":"2021120902151140300_R59","doi-asserted-by":"crossref","unstructured":"Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem.\u20081997;247:625\u2013634","DOI":"10.1111\/j.1432-1033.1997.00625.x"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/4\/1243\/1072685\/zpe00406001243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/4\/1243\/1072685\/zpe00406001243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T10:24:21Z","timestamp":1639045461000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/4\/1243\/70922\/Targeted-Short-Term-Fluconazole-Prophylaxis-Among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,4,1]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-1969","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}